Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SURMOUNT-MMO

SURMOUNT-MMO

Tirzepatide · Obesity, morbidity and mortality

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
Obesity, morbidity and mortality
Official title
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
active not recruiting · 2022-10 → 2027-10
Participants
15374
Registry
NCT05556512

Ongoing outcome trial

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
SURMOUNT-MMOTirzepatideObesity, morbidity and mortality
Obesity without diabetes (T2D excluded), established CVD or risk factors
Composite of death and CV events15374active not recruiting2027-10NCT05556512

No results yet; the primary completion date comes from the registry.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SURMOUNT-MMO. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-mmo/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.